Latest news from ReproCELL
NEW PRODUCT ANNOUNCEMENT:
Stemgent StemRNA™-SR Reprogramming Kit
We are pleased to announce that Stemgent Inc. (Cambridge, MA), a ReproCELL Group Company (Yokohama, Japan – JASDAQ: 4978) has launched its new Stemgent StemRNA™-SR Reprogramming Kit , the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type. This non-viral, non-DNA reprogramming kit combines self-replicative RNA (srRNA) and microRNA technology, providing stem cell researchers with a safe, flexible and cost-effective cellular reprogramming method applicable to both human fibroblasts and blood-derived endothelial progenitor cells (EPCs). EPCs are uniquely genetically stable and can be efficiently established from fresh or cryopreserved human peripheral and cord blood. This latest innovation was unveiled at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 24 – 27 in Stockholm, Sweden.
“The combination of readily-available patient blood samples with integration-free RNA reprogramming technology supported by the Stemgent StemRNA-SR Reprogramming Kit and protocol is a great step forward for researchers developing clinically relevant iPS cell lines” said Joseph Gentile (Chief Executive Officer, Stemgent).
About Stemgent (A ReproCELL Group Company)
Stemgent is engaged in working alongside some of the world’s leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. Its mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide. Stemgent stem cell reagents are available to customers worldwide.
For more information, visit: www.stemgent.com.
Contacts – Stemgent Inc.
Roseann Vardaro, Director of Product Marketing
Sedgefield, UK. April 2015 – Market leading 3D cell culture company Reinnervate Ltd, part of the ReproCELL group, today announced that a rocket carrying its Alvetex® Scaffold technology blasted into Space this week. Alvetex will be used in experiments on board the International Space Station (ISS).
Alvetex Scaffold products allow researchers to overcome the limitations of growing cells on flat surfaces by creating a unique three dimensional (3D) surface that allows cells to form tissue-like structures in an in vitro setting. A team from Massachusetts General Hospital investigating bone loss during bed rest and diseases such as osteoporosis, has incorporated Alvetex Scaffold in experiments 150 miles above the surface of the Earth after the equipment is delivered to the ISS by the SpaceX Dragon capsule.
Visit our news archive